Why the study?
Limiting profibrotic remodeling after ischemia is critical to prevent diastolic dysfunction, and whether MSC exosomes protect against profibrotic events was unknown.
Does MSC exosome treatment reduce postischemic fibrosis and inflammatory signals in mouse hearts subjected to ischemia?
Does MSC exosome treatment reduce postischemic fibrosis and inflammatory signals in mouse hearts subjected to ischemia?
MSC exosomes suppress inflammatory signals and promote pro-reparative ECM remodeling to reduce fibrotic scar formation in ischemic mouse hearts.
MSC exosomes remain investigational for post-ischemic fibrosis; leaves open translation to human diastolic dysfunction prevention.
After an ischemic event, there is activation of fibroblasts leading to scar formation. It is critical to limit the profibrotic remodeling and activate the reparative remodeling phase to limit cardiac diastolic dysfunction. Mesenchymal stem cell (MSC) exosomes offer significant protection against ischemia-related systolic dysfunction. Here, we studied if MSC exosomes would offer protection against profibrotic events in mouse hearts subjected to acute ischemia [1 h left coronary artery (LCA) occlusion] or chronic ischemia (7 days LCA occlusion). After acute ischemia, there was activation of inflammatory signals, more in the peri-infarct than in the infarct area, in the saline (vehicle)-treated mice. At the same time, there was expression of cardiac remodeling signals (vimentin, collagens-1 and -3, and fibronectin), more in the infarct area. Treatment with MSC exosomes before LCA ligation suppressed inflammatory signals during acute and chronic ischemia. Furthermore, exosome treatment promoted pro-reparative cardiac extracellular matrix (ECM) remodeling in both infarct and peri-infarct areas by suppressing fibronectin secretion and by modulating collagen secretion to reduce fibrotic scar formation through altered cellular signaling pathways. Proteomics study revealed intense expression of IL-1β and activation of profibrotic signals in the saline-treated hearts and their suppression in MSC exosome-treated hearts. To our knowledge, this is the first report on the infarct and peri-infarct area proteomics of ischemic mice hearts to explain MSC exosome-mediated suppression of scar formation in the ischemic mouse hearts.
No takes yet. Share an insight, caveat, or question.
Kore et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: